The company’s shares closed at Rs 833 on the Bombay Stock Exchange. On May 18, the company had announced it would hold its board meeting on...

According to IMS sales data, Lupin is ranked second with 12.4 per cent market share of the overall anti-asthma segment within the Indian ph...

Delhi High Court has reserved its decision on a high-profile patent case that pitted Swiss drug maker Novartis against Cipla over its respi...

In fact, pharma MNCs in India are growing faster than their local counterparts: according to AIOCD data, they expanded 13.8 per cent in Jul...

"We will not give you an interim order. We will hear it on an early date and dispose it of. Notice. Renotify on February 5," the bench said.

The matter was mentioned before a bench of Justices Badar Durrez Ahmed and Sanjeev Sachdeva who directed that the plea be listed before the...

Sources said the court on Friday issued an interim injunction directing Cipla to stop the sale of the generic drug in the market.

HC temporarily restrained Cipla from manufacturing, importing or selling any drug containing the chemical Indacaterol.

Indian markets are expected to trade higher. Here is a list of ten stocks which are likely to be in focus today.

The Delhi High Court has reserved its verdict on a dispute between pharma firms Novartis and Cipla over manufacturing of the drug Indacater...

Cipla's proposal for the medicines under section 92 of the Patents Act may not be "fit" to pass legal scrutiny- Health ministry

Japanese firm Otsuka Pharmaceuticals, Myers-Squibb, Novartis are deferring launch of medicines critical for treatment of serious non-commun...

Novartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent off...

Cipla has launched low-cost generic version of Novartis's respiratory drug Indacaterol while asking government to revoke patents over the m...

Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...

Indian markets are expected to trade in a range. Here is a list of fifteen stocks which are likely to be in focus today.

Novartis India has over the past year launched three successful patented drugs and over 12 generic drugs that have helped it expand its pre...